Pharmacokinetic drug–drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management

References

• CorsonelloAPedoneCCoricaFIncalziRAPolypharmacy in elderly patients at discharge from the acute care hospitalTher Clin Risk Manag20073119720318360627
   PubMedGoogle Scholar
• KohYKuttyFBLiSCDrug-related problems in hospitalized patients on polypharmacy: the influence of age and genderTher Clin Risk Manag200511394818360542
   PubMedGoogle Scholar
• KöberleinJGottschallMCzarneckiKThomasABergmannAVoigtKGeneral practitioners’ views on polypharmacy and its consequences for patient health careBMC Fam Pract201314111923947640
   PubMedGoogle Scholar
• LiWZengSYuLSZhouQPharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk managementTher Clin Risk Manag2013925927123745048
   PubMed Web of Science ®Google Scholar
• Joint Commission InternationalJoint Commission International Accreditation Standards for Hospitals; Standards Lists Version4th edOak Brook, ILJoint Commission International2010 Available from: http://www.jointcommissioninternational.org/common/pdfs/jcia/IAS400_Stan-dards_Lists_Only.pdfAccessed March 20, 2013
   Google Scholar
• LeungASchaeferEWTempelhofMWStoneNJEmphasizing statin safety in the hospitalized patient: a reviewAm J Med2012125984585322938925
   PubMed Web of Science ®Google Scholar
• HennemanAThornbyKARisk of hypotension with concomitant use of calcium-channel blockers and macrolide antibioticsAm J Health Syst Pharm201269121038104322644980
   PubMed Web of Science ®Google Scholar
• fda.gov [homepage on the Internet]FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury2011 [updated December 15, 2011; cited October 4, 2013] Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htmAccessed November 17, 2013
   Google Scholar
• WiwanitkitSWiwanitkitVInappropriate concomitant use of amlodipine and simvastatin: A report on its incidence in a primary care unitIndian J Endocrinol Metab201115Suppl 4S40922145149
   PubMedGoogle Scholar
• LeeCKChoiJSChoiDHEffects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatinIndian J Pharmacol201244562462823112426
   PubMed Web of Science ®Google Scholar
• ChungJWYangSHChoiJSEffects of lovastatin on the pharmacokinetics of nicardipine in ratsBiopharm Drug Dispos201031743644120824619
   PubMed Web of Science ®Google Scholar
• ZhouLXFinleyDKHassellAEHoltzmanJLPharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteersJ Pharmacol Exp Ther199527311211277714757
   PubMed Web of Science ®Google Scholar
• ZivianiLDa RosLSquassanteLMilleriSCugolaMIavaroneLEThe effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjectsBr J Clin Pharmacol200151214715211259986
   PubMed Web of Science ®Google Scholar
• SonHLeeDLimLAJangSBRohHParkKDevelopment of a Pharmacokinetic Interaction Model for Co-administration of Simvastatin and AmlodipineDrug Metab Pharmacokinet Epub8202013
   PubMed Web of Science ®Google Scholar
• KatohMNakajimaMShimadaNYamazakiHYokoiTInhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactionsEur J Clin Pharmacol20005511–1284385210805063
   PubMed Web of Science ®Google Scholar
• APO-Lercanidipine (lercanidipine hydrochloride) tablets [product information]North RydeApotex Pty Ltd2010
   Google Scholar
• BoralliVBCoelhoEBSampaioSAMarquesMPLanchoteVLEnantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteersJ Clin Pharmacol200949220521119033449
   PubMed Web of Science ®Google Scholar
• CADUET® (amlodipine besylate/atorvastatin calcium) tablets [patient information]New York, NYPfizer Inc2012
   Google Scholar
• Nimotop® (nimodipine) Prescribing Information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018869s014lbl.pdfAccessed October 4, 2013
   Google Scholar
• LiuXQRenYLQianZYWangGJEnzyme kinetics and inhibition of nimodipine metabolism in human liver microsomesActa Pharmacol Sin20002169069411501176
   PubMed Web of Science ®Google Scholar
• KatohMNakajimaMYamazakiHYokoiTInhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4Pharm Res2000171189119711145223
   PubMed Web of Science ®Google Scholar
• Motens Tablets 4mg. Prescribing Information Available from: http://www.medicines.org.uk/emc/medicine/298/SPCAccessed October 5, 2013
   Google Scholar
• ZOCOR (simvastatin) Tablets. Product Information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s077s082lbl.pdfAccessed October 5, 2013
   Google Scholar
• NishioSWatanabeHKosugeKUchidaSHayashiHOhashiKInteraction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertensionHypertens Res200528322322716097365
   PubMed Web of Science ®Google Scholar
• ParkCGLeeHChoiJWLeeSJKimSHLimHENon-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatinInt J Clin Pharmacol Ther201048849750320650039
   PubMed Web of Science ®Google Scholar
• SugiyamaYMimuraNKuwabaraTKobayashiHUshikiJFuseEEffect of benidipine on simvastatin metabolism in human liver microsomesDrug Metab Pharmacokinet200722319920517603221
   PubMed Web of Science ®Google Scholar
• ChungMCalcagniAGluePBramsonCBioavailability of amlodipine besylate/atorvastatin calcium combination tabletJ Clin Pharmacol20064691030103716920898
   PubMed Web of Science ®Google Scholar
• ZhouQRuanZRYuanHZengSCYP2C9*3(1075A.C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteersArzneimittelforschung2012621151952422941809
   PubMed Web of Science ®Google Scholar
• UesawaYMohriKRelationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juiceYakugaku Zasshi2008128111712218176062
   PubMed Web of Science ®Google Scholar
• HarmszeAMRobijnsKvan WerkumJWThe use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-responseThromb Haemost2010103592092520352154
   PubMed Web of Science ®Google Scholar
• ZhouQRuanZRJiangBYuanHZengSSimvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphismsPharmazie201368212412823469684
   PubMed Web of Science ®Google Scholar
• ZuoXCZhouYNZhangBKEffect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and AmlodipineDrug Metab Pharmacokinet201328539840523438946
   PubMed Web of Science ®Google Scholar
• WalskyRLObachRSHylandRSelective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugsDrug Metab Dispos2012401686169722645092
   PubMed Web of Science ®Google Scholar
• JacobsonTAComparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsAm J Cardiol20049491140114615518608
   PubMed Web of Science ®Google Scholar
• HochMHoeverPTheodorRDingemanseJAlmorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatinEur J Clin Pharmacol20136961235124523334403
   PubMed Web of Science ®Google Scholar
• TengRMitchellPDButlerKAPharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteersEur J Clin Pharmacol201369347748722922682
   PubMed Web of Science ®Google Scholar
• OhnoYHisakaASuzukiHGeneral framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugsClin Pharmacokinet200746868169617655375
   PubMed Web of Science ®Google Scholar
• ZhouQChenQXRuanZRYuanHXuHMZengSCYP2C9*3 (1075A>C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokineticsPharmazie201368318719423556337
   PubMed Web of Science ®Google Scholar
• ZhouQRuanZRYuanHXuDHZengSABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c>A are determinants of inter-subject variability in rosuvastatin pharmacokineticsPharmazie201368212913423469685
   PubMed Web of Science ®Google Scholar